FLT3 and acute myeloid leukemia: Post-HSCT maintenance with sorafenib emerged in recent years as a way to improve prognosis by diminishing relapse risk of FLT3-ITD AML, as reported in early studies (4–6) as well as phase II (7) and III (8) clinical trials.